{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:28:44Z","timestamp":1784694524849,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T00:00:00Z","timestamp":1326931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00262-012-1201-0","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T16:10:35Z","timestamp":1326903035000},"page":"1243-1253","source":"Crossref","is-referenced-by-count":37,"title":["Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Emilia","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Villabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Bergfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe V.","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"issue":"2","key":"1201_CR1","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255\u2013288. doi: 10.1210\/er.22.2.255","journal-title":"Endocr Rev"},{"issue":"1","key":"1201_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","volume":"23","author":"JD Seidman","year":"2004","unstructured":"Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23(1):41\u201344. doi: 10.1097\/01.pgp.0000101080.35393.16","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"1201_CR3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ejso.2006.03.041","volume":"32","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Linch M, Kaye SB (2006) Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 32(8):875\u2013886. doi: 10.1016\/j.ejso.2006.03.041","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1201_CR4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2002","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics. CA Cancer J Clin 55(2):74\u2013108. doi: 55\/2\/74","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1201_CR5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0002-9378(94)70104-0","volume":"170","author":"AL Herbst","year":"1994","unstructured":"Herbst AL (1994) The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 170(4):1099\u20131105. doi: S0002937894000955 ; Discussion 1105\u20131097","journal-title":"Am J Obstet Gynecol"},{"issue":"5 Pt 1","key":"1201_CR6","first-page":"783","volume":"91","author":"G Coukos","year":"1998","unstructured":"Coukos G, Rubin SC (1998) Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 91(5 Pt 1):783\u2013792","journal-title":"Obstet Gynecol"},{"issue":"23","key":"1201_CR7","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1158\/1078-0432.CCR-08-0479","volume":"14","author":"MJ Callahan","year":"2008","unstructured":"Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC (2008) Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14(23):7667\u20137673. doi: 10.1158\/1078-0432.CCR-08-0479","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1201_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.02.004","volume":"103","author":"Z Gamzatova","year":"2006","unstructured":"Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV (2006) Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103(1):145\u2013150. doi: 10.1016\/j.ygyno.2006.02.004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1201_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1385\/MO:21:1:49","volume":"21","author":"L Petris De","year":"2004","unstructured":"De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, Van Der Zanden HG, Masucci G (2004) Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 21(1):49\u201352. doi: 10.1385\/MO:21:1:49","journal-title":"Med Oncol"},{"issue":"3","key":"1201_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0039.2007.00875.x","volume":"70","author":"Z Gamzatova","year":"2007","unstructured":"Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L, Dalianis T, Bergfeldt K, Masucci GV (2007) Analysis of HLA class I\u2013II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tiss Antigens 70(3):205\u2013213. doi: 10.1111\/j.1399-0039.2007.00875.x","journal-title":"Tiss Antigens"},{"key":"1201_CR11","author":"GV Masucci","year":"2010","unstructured":"Masucci GV, Andersson E, Villabona L, Helgadottir H, Bergfeldt K, Cavallo F, Forni G, Ferrone S, Aniruddha C, Seliger B, Kiessling R (2010) Survival of the fittest or best adapted-HLA-dependent tumour development. J Nucl Acids Investig. doi: 10.4081\/jnai.2010.e9","journal-title":"J Nucl Acids Investig"},{"issue":"1","key":"1201_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-5002(00)00204-X","volume":"32","author":"T So","year":"2001","unstructured":"So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32(1):39\u201346","journal-title":"Lung Cancer"},{"issue":"6","key":"1201_CR13","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/1097-0142(197706)39:6<2345::AID-CNCR2820390605>3.0.CO;2-W","volume":"39","author":"CN Rogentine Jr","year":"1977","unstructured":"Rogentine CN Jr, Dellon AL, Chretien PB (1977) Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5. A 2-year prospective study. Cancer 39(6):2345\u20132347","journal-title":"Cancer"},{"issue":"10","key":"1201_CR14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00262-009-0669-8","volume":"58","author":"H Helgadottir","year":"2009","unstructured":"Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV (2009) The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58(10):1599\u20131608. doi: 10.1007\/s00262-009-0669-8","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1201_CR15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/00005537-200204000-00011","volume":"112","author":"M Tisch","year":"2002","unstructured":"Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H (2002) Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 112(4):651\u2013657. doi: 10.1097\/00005537-200204000-00011","journal-title":"Laryngoscope"},{"issue":"4","key":"1201_CR16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1998.16.4.1430","volume":"16","author":"DS Hoon","year":"1998","unstructured":"Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL (1998) Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16(4):1430\u20131437","journal-title":"J Clin Oncol"},{"issue":"6","key":"1201_CR17","first-page":"587","volume":"9","author":"JE Lee","year":"2002","unstructured":"Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI (2002) Presence of the human leukocyte antigen class II gene DRB1* 1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 9(6):587\u2013593","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"1201_CR18","first-page":"6561","volume":"52","author":"FM Marincola","year":"1992","unstructured":"Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR (1992) HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 52(23):6561\u20136566","journal-title":"Cancer Res"},{"issue":"7","key":"1201_CR19","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.1992.10.7.1158","volume":"10","author":"MS Mitchell","year":"1992","unstructured":"Mitchell MS, Harel W, Groshen S (1992) Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10(7):1158\u20131164","journal-title":"J Clin Oncol"},{"issue":"8","key":"1201_CR20","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2002.08.072","volume":"20","author":"JA Sosman","year":"2002","unstructured":"Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20(8):2067\u20132075. doi: 10.1200\/jco.2002.08.072","journal-title":"J Clin Oncol"},{"issue":"2","key":"1201_CR21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/bjc.1997.46","volume":"75","author":"C Bain","year":"1997","unstructured":"Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC (1997) Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75(2):283\u2013286","journal-title":"Br J Cancer"},{"issue":"5","key":"1201_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/108497801753354302","volume":"16","author":"A Franzke","year":"2001","unstructured":"Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J (2001) HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16(5):401\u2013409","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"1201_CR23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1442-2042.1996.tb00572.x","volume":"3","author":"T Onishi","year":"1996","unstructured":"Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Int J Urol 3(6):435\u2013440","journal-title":"Int J Urol"},{"issue":"2","key":"1201_CR24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","volume":"57","author":"AM Mehta","year":"2008","unstructured":"Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren G (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57(2):197\u2013206","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1201_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2370.1998.00108.x","volume":"25","author":"L Montoya","year":"1998","unstructured":"Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N (1998) Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 25(5):329\u2013337","journal-title":"Eur J Immunogenet"},{"issue":"4","key":"1201_CR26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.leu.2400965","volume":"12","author":"J Cortes","year":"1998","unstructured":"Cortes J, Fayad L, Kantarjian H, O\u2019Brien S, Lee MS, Talpaz M (1998) Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12(4):455\u2013462","journal-title":"Leukemia"},{"issue":"5","key":"1201_CR27","first-page":"412","volume":"69","author":"A Campo Del","year":"2007","unstructured":"Del Campo A, Mendez R, Aptsiauri N, Rodriguez T, Zinchenko S, Garcia A, Gallego A, Gaudernack G, Ward S, Ruiz-Cabello F, Garrido F (2007) HLA total loss: different molecular mechanisms found in different tumor cell lines. Tiss Antigens 69(5):412","journal-title":"Tiss Antigens"},{"issue":"1","key":"1201_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-002-0332-0","volume":"52","author":"T Cabrera","year":"2003","unstructured":"Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52(1):1\u20139. doi: 10.1007\/s00262-002-0332-0","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"1201_CR29","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-07-4433","volume":"14","author":"LY Han","year":"2008","unstructured":"Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK (2008) HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14(11):3372\u20133379. doi: 10.1158\/1078-0432.CCR-07-4433","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1201_CR30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ygyno.2008.04.043","volume":"110","author":"N Leffers","year":"2008","unstructured":"Leffers N, Lambeck AJ, de Graeff P, Bijlsma AY, Daemen T, van der Zee AG, Nijman HW (2008) Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol 110(3):365\u2013373. doi: 10.1016\/j.ygyno.2008.04.043","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1201_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)00300-3","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet 70(2):209\u2013262","journal-title":"Int J Gynaecol Obstet"},{"key":"1201_CR32","volume-title":"Tumours of the breast and female genital organs","author":"F Tavassoli","year":"2003","unstructured":"Tavassoli F, Devilee P (2003) Tumours of the breast and female genital organs. IARC Press, Lyon. ISBN 9283224124"},{"issue":"5","key":"1201_CR33","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.4049\/jimmunol.130.5.2471","volume":"130","author":"LA Lampson","year":"1983","unstructured":"Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 130(5):2471\u20132478","journal-title":"J Immunol"},{"issue":"4","key":"1201_CR34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.171.4.1918","volume":"171","author":"F Perosa","year":"2003","unstructured":"Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171(4):1918\u20131926","journal-title":"J Immunol"},{"issue":"3","key":"1201_CR35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0161-5890(98)00026-1","volume":"35","author":"MF Sernee","year":"1998","unstructured":"Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35(3):177\u2013188. doi: S0161589098000261","journal-title":"Mol Immunol"},{"issue":"7","key":"1201_CR36","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.4049\/jimmunol.137.7.2299","volume":"137","author":"NJ Stam","year":"1986","unstructured":"Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137(7):2299\u20132306","journal-title":"J Immunol"},{"issue":"1","key":"1201_CR37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/emm.2002.3","volume":"34","author":"YS Lee","year":"2002","unstructured":"Lee YS, Kim TE, Kim BK, Park TG, Kim GM, Jee SB, Ryu KS, Kim IK, Kim JW (2002) Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 34(1):18\u201326","journal-title":"Exp Mol Med"},{"key":"1201_CR38","unstructured":"Garrido F, Cabrera T, Accolla RS et al. (1997) HLA and cancer. In: 12th International histocompatibility workshop study\u2014HLA, Jun, St. Malo, France, vol I, 1996 edn, pp 445\u2013452"},{"issue":"1","key":"1201_CR39","first-page":"75","volume":"3","author":"S Pecorelli","year":"1998","unstructured":"Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepherd J, Sideri M, Benedet J (1998) Carcinoma of the ovary. J Epidemiol Biostat 3(1):75\u2013102","journal-title":"J Epidemiol Biostat"},{"key":"1201_CR40","volume-title":"The history and geography of human genes","year":"1994","unstructured":"Cavalli-Sforza LL, Menozzi P, Piazza A (eds) (1994) The history and geography of human genes. Princetown University Press, Princetown"},{"key":"1201_CR41","volume-title":"American Indian MtDNA, Y chromosome genetic data, and the peopling of North America","year":"2004","unstructured":"Jones PN (ed) (2004) American Indian MtDNA, Y chromosome genetic data, and the peopling of North America. B\u00e4uu Institute, Boulder"},{"issue":"1","key":"1201_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-065X.1995.tb00674.x","volume":"143","author":"P Parham","year":"1995","unstructured":"Parham P, Adams EJ, Arnett KL (1995) The origins of HLA-A, B, C polymorphism. Immunol Rev 143(1):141\u2013180. doi: 10.1111\/j.1600-065X.1995.tb00674.x","journal-title":"Immunol Rev"},{"issue":"3","key":"1201_CR43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58(3):449\u2013459. doi: 10.1007\/s00262-008-0583-5","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"1201_CR44","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/1078-0432.CCR-06-2087","volume":"13","author":"P Rolland","year":"2007","unstructured":"Rolland P, Deen S, Scott I, Durrant L, Spendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13(12):3591\u20133596. doi: 10.1158\/1078-0432.CCR-06-2087","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1201_CR45","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/PAS.0b013e318222a634","volume":"35","author":"JP North","year":"2011","unstructured":"North JP, Vetto JT, Murali R, White KP, White CR Jr, Bastian BC (2011) Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Am J Surg Pathol 35(8):1146\u20131150. doi: 10.1097\/PAS.0b013e318222a634","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1201_CR46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1399-0039.2009.01438.x","volume":"75","author":"C Menier","year":"2010","unstructured":"Menier C, Rouas-Freiss N, Favier B, LeMaoult J, Moreau P, Carosella ED (2010) Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tiss Antigens 75(3):201\u2013206. doi: 10.1111\/j.1399-0039.2009.01438.x","journal-title":"Tiss Antigens"},{"issue":"12","key":"1201_CR47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.humimm.2009.07.021","volume":"70","author":"C Menier","year":"2009","unstructured":"Menier C, Prevot S, Carosella ED, Rouas-Freiss N (2009) Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol 70(12):1006\u20131009. doi: 10.1016\/j.humimm.2009.07.021","journal-title":"Hum Immunol"},{"issue":"2 Pt 1","key":"1201_CR48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.ju.0000094807.95420.fe","volume":"171","author":"D Atkins","year":"2004","unstructured":"Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171(2 Pt 1):885\u2013889. doi: 10.1097\/01.ju.0000094807.95420.fe","journal-title":"J Urol"},{"issue":"5","key":"1201_CR49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/path.2142","volume":"211","author":"T Hirata","year":"2007","unstructured":"Hirata T, Yamamoto H, Taniguchi H, Horiuchi S, Oki M, Adachi Y, Imai K, Shinomura Y (2007) Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol 211(5):516\u2013523. doi: 10.1002\/path.2142","journal-title":"J Pathol"},{"issue":"2","key":"1201_CR50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/intimm\/2.2.113","volume":"2","author":"NJ Stam","year":"1990","unstructured":"Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL (1990) HLA-A and -B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 2(2):113\u2013125","journal-title":"Int Immunol"},{"issue":"12","key":"1201_CR51","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/01.LAB.0000043124.75633.ED","volume":"82","author":"AG Menon","year":"2002","unstructured":"Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82(12):1725\u20131733","journal-title":"Lab Invest"},{"issue":"8","key":"1201_CR52","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2003-07-2500","volume":"103","author":"C Demanet","year":"2004","unstructured":"Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S (2004) Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103(8):3122\u20133130. doi: 10.1182\/blood-2003-07-25002003-07-2500","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-012-1201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-012-1201-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-012-1201-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T19:07:34Z","timestamp":1686683254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-012-1201-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s00262-012-1201-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}